Cargando…

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation

BACKGROUND: Bleeding is a major complication of warfarin therapy. Assessing the cost of warfarin-associated bleeding may more fully describe the costs associated with warfarin use. OBJECTIVES: To assess health care costs related to warfarin-associated bleeding in patients with newly diagnosed atrial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghate, Sameer R., Biskupiak, Joseph, Ye, Xiangyang, Kwong, Winghan J., Brixner, Diana I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437352/ https://www.ncbi.nlm.nih.gov/pubmed/22050392 http://dx.doi.org/10.18553/jmcp.2011.17.9.672

Ejemplares similares

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective
por: Casciano, Julian P., et al.
Publicado: (2013)

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
por: Gilligan, Adrienne M., et al.
Publicado: (2017)

Impact of Atrial Fibrillation on Stroke‐Related Healthcare Costs
por: Sussman, Matthew, et al.
Publicado: (2013)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
por: Gallagher, Arlene M, et al.
Publicado: (2014)

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
por: Simon, Teresa A., et al.
Publicado: (2016)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
por: Lai, Hoang M, et al.
Publicado: (2009)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective
por: McAdam-Marx, Carrie, et al.
Publicado: (2011)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes
por: Tsai, Chieh, et al.
Publicado: (2017)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation
por: Liu, Jia, et al.
Publicado: (2021)

The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
por: Björholt, Ingela, et al.
Publicado: (2007)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
por: Deitelzweig, Steve, et al.
Publicado: (2018)

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
por: Reynolds, Shannon L., et al.
Publicado: (2017)

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
por: Wang, Kaijun, et al.
Publicado: (2017)

Associations of anaemia with bleeding and thrombotic complications in patients with atrial fibrillation treated with warfarin: a registry-based nested case–control study
por: Helin, Tuukka Antero, et al.
Publicado: (2023)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
por: Pyykönen, Mikko, et al.
Publicado: (2021)

Atrial Fibrillation Patients Treated With Long‐Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long‐Term Warfarin for Other Indications
por: Bunch, T. Jared, et al.
Publicado: (2016)

A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
por: Claxton, J’Neka S., et al.
Publicado: (2018)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation
por: Liu, Sian-De, et al.
Publicado: (2022)

Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
por: Reddy, Vivek Y., et al.
Publicado: (2016)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Estimation of healthcare‐related charges in women with BRCA mutations and breast cancer
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011
por: Hansen, Peter Wæde, et al.
Publicado: (2018)

Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta‐analysis
por: Jiang, Hongcheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nbj644q170opo6n44b1civ8uds